Trump’s Executive Order Limiting Medicare Drug Payments Faces Hurdles
Under test payment model, Medicare would pay no more than most-favored-nation price for Part B and Part D drugs, but how and when the model program would be implemented remains unclear. BIO may pursue legal action as questions on how plan would be implemented and if the administration will provide notice and comment period for stakeholder input remain.
You may also be interested in...
The latest flurry of Executive Order activity on drug pricing reinforces the message that the President wants to own the headlines for being tough on the drug industry as Election Day looms. Looking for substance beyond that goal is a fool’s errand – but the headlines could still have significant consequences no matter who wins in November.
The Swiss major's pharma chief Bill Anderson tells Scrip that the goal for the firm over the next decade is to deliver twice as many medicines at a much lower cost to society.
Whether an opening gambit for negotiation or the most industry is willing to concede, proposals being offered by industry to replace the Trump Administration’s plan to pursue international reference pricing for Part B drugs seem modest.